Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus LANABIOTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus LANABIOTIC.
CHLOROMYXIN vs LANABIOTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
LANABIOTIC is a lantibiotic that inhibits bacterial cell wall synthesis by binding to lipid II, a key precursor in peptidoglycan biosynthesis, thereby disrupting cell wall integrity and causing cell death.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is 6-8 hours in patients with normal renal function; extends to 20-40 hours in severe renal impairment (CrCl <30 mL/min).
CHLOROMYXIN is not a recognized drug. No data available.
Renal excretion of unchanged drug accounts for 60-80% of elimination; biliary/fecal excretion accounts for 15-30%.
Category C
Category C
Antibiotic
Antibiotic